Berlex buys CompleGen system

- Last updated on GMT

Related tags: Pharmacology, Drug discovery

Genetics-based drug discovery company CompleGen is to supply Berlex
Biosciences, a US affiliate of German company Schering, with a high
throughput assay system for discovery of compounds active against a
novel target identified by Berlex.

Genetics-based drug discovery company CompleGen is to supply Berlex Biosciences​, a US affiliate of German company Schering, with a high throughput assay system for discovery of compounds active against a novel target identified by Berlex.

Announcing the agreement this week the two companies said that Berlex has paid CompleGen a fee, with further terms and payments to be agreed if suitable compounds, identified during the project, are developed and commercialised.

The target assay uses CompleGen's XenoGene system which identifies compounds that are specifically active against the target protein, but not other cellular components.

"We are very happy to be working with Berlex' Oncology Research group and their skilled compound screening team,"​ said Dr John Swindle, CompleGen's chief scientific officer.

Related topics: Preclinical Research

Follow us

Products

View more

Webinars